TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01125423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Subjects with Fibromyalgia will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin Biopsy
Description: Control Subjects will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin Biopsy
Description: Control Subjects will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
Study: NCT00698958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
Description: Ambulatory adaptation to non- invasive mechanical ventilation for 7 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hospital based adaptation to non- invasive mechanical ventilation for 7 days
Description: Hospital based adaptation to non- invasive mechanical ventilation for 7 days
Study: NCT01599650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: laser photocoagulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: laser photocoagulation
Study: NCT01243944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib tablets
Description: Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy

Intervention type: OTHER
Group type: OTHER
Intervention: Best Available Therapy (BAT)
Description: Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
Study: NCT04526171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaparshun
Description: Participants in the intervention clusters were encouraged to improve their existing toilets.
Study: NCT01094600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synthetic Human Secretin
Description: Twelve patients will undergo S-MRCP, at a dose of 0.2 ucg/kg per exam. Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
Study: NCT04107844

Intervention type: DIAGNOSTIC_TEST
Intervention: Novel facilitating agility dual-task test combined with already known tests
Description: We will investigate if a combination of a novel Dual-task test combined with already known tests can identify more athletes, not ready to return to play, although symptoms of concussion have stopped.

Intervention type: DIAGNOSTIC_TEST
Intervention: Novel facilitating agility dual-task test combined with already known tests
Description: We will investigate if a combination of a novel Dual-task test combined with already known tests can identify more athletes, not ready to return to play, although symptoms of concussion have stopped.
Study: NCT03652324

Intervention type: OTHER
Group type: OTHER
Intervention: method
Description: to compare the use of general anesthesia and deep sedation
Study: NCT02305303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diary
Description: A diary written prospectively during the ICU stay by the staff and relatives
Study: NCT01581476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: 10mg daily for a minimum period of 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor
Description: Starting dose of 5mg daily rising after 14 days to 10mg daily providing it is well tolerated for a minimum period of 2 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive statin placebo and ACEI placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Combination therapy
Description: Participants receive both active statin and active ACEI. Dose for Statins is 10mg daily. Dosing for ACEI starts at 5mg daily rising to 10mg after 14 days providing it is well tolerated. Both interventions last for a minimum of 2 years.
Study: NCT01326624

Intervention type: DEVICE
Intervention: wearable defibrillator (LifeVest)
Description: LifeVest wearable defibrillator for unattended treatment of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation

Intervention type: DEVICE
Intervention: wearable defibrillator (LifeVest)
Description: LifeVest wearable defibrillator for unattended treatment of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation

Intervention type: DEVICE
Intervention: wearable defibrillator (LifeVest)
Description: LifeVest wearable defibrillator for unattended treatment of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation

Intervention type: DEVICE
Intervention: wearable defibrillator (LifeVest)
Description: LifeVest wearable defibrillator for unattended treatment of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation
Study: NCT03767959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chen's U-Suture
Description: Chen's U-Suture is a new technique of the invaginated end-to-end pancreaticojejunostomy with transpancreatic transverse U-sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic pancreatic duct to mucosa
Description: A Classical anastomosis technique for Pancreaticojejunostomy
Study: NCT03149640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled amikacin
Description: Once a day, inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
Study: NCT04683055

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification combined with trabeculectomy
Description: Patients with chronic angle closure glaucoma assigned to this group will have fornex based trabeculectomy at superior limbus and then phacoemulsification via temporal incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsificaiton combined with ab-externo trabeculotomy
Description: Patients with chronic angle closure glaucoma assigned to this group will have Deep Sclerectomy with ab externo trabeculotomy at superior limbus and then phacoemulsification via temporal incision
Study: NCT03495908

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VGo
Description: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VGo
Description: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.
Study: NCT01595620

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Thermal
Description: Thermal sensation/pain testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thermal
Description: Thermal sensation/pain testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thermal
Description: Thermal sensation/pain testing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electrical
Description: Electrical sensation/pain testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical
Description: Electrical sensation/pain testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical
Description: Electrical sensation/pain testing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin
Description: Intradermal Capsaicin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: Intradermal Capsaicin
Study: NCT00870714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
Study: NCT01595620

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: Intradermal Capsaicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: Active THC (0.01 mg/kg) administered over 10 minutes
Study: NCT02440919

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperoxygenation 100% FiO2
Description: Endotracheal suction associated with Hyperoxygenation involved supplying 100% oxygen.

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperoxygenation 20% FiO2
Description: Endotracheal suction associated with Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
Study: NCT01595620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: Active THC (0.03 mg/kg) administered over 10 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: small amount of alcohol with no THC, administered over 10 minutes
Study: NCT03767491

Intervention type: DEVICE
Group type: OTHER
Intervention: Smartphone-delivered CBT for OCD
Description: 12-week Smartphone-delivered CBT for OCD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for OCD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered CBT for OCD
Description: 12-week Smartphone-delivered CBT for OCD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for OCD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
Study: NCT03753958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: aPDT
Description: aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
Study: NCT02334748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: canakinumab
Study: NCT02573987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen/nitrous oxide equimolar mix
Description: an experimental strategy inhalation by means of a breathing mask diffusing MEOPA
Study: NCT02871466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stem cells infusion
Study: NCT02573987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: standard strategy by local injection anesthesia of lidocaine
Study: NCT01840592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study: NCT01177501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Six sequential doses established in the absence of limiting toxicity, as follows : 7.5 - 8.0 - 8.5 - 9.0 - 10.0 mg/m²
Study: NCT03246009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHSA/GCSF
Description: single injection-1.8mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHSA/GCSF
Description: single injection-2.1mg
Study: NCT04762771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine dosing = 0.6 mg bid x 30 days Decrease dose to 0.3-0.6 mg daily or every other day in setting of gastrointestinal intolerance (nausea, diarrhea, emesis, abdominal discomfort) Decrease dose to 0.6 mg daily in the setting of weak or moderate CYP3A4 inhibitor Decrease dose to 0.3 mg daily in the setting of strong CYP3A4, P-glycoprotein inhibitors, or protease inhibitors Decrease dose to 0.3 mg daily in the setting of chronic kidney disease (CKD) stage ≥ 4 (CrCl ≤ 30 ml/min) or liver failure (aspartate aminotransferase /alanine aminotransferase \> 3x normal).~Decrease dose to 0.6 mg every 14 days in patients with end stage renal disease (ESRD) or requiring dialysis Route of Administration: oral
Study: NCT03246009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHSA/GCSF
Description: single injection-2.4mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHSA/GCSF
Description: multiple injection-1.8mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHSA/GCSF
Description: multiple injection-2.1mg
Study: NCT03359473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2881078
Description: GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2881078
Description: GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.
Study: NCT03246009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHSA/GCSF
Description: multiple injection-2.4mg
Study: NCT00984841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored letter

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tailored letter
Study: NCT04616144

Intervention type: DEVICE
Group type: OTHER
Intervention: Fresh Corneal Lenticule Implantation using Relex-Smile VisuMax Femtosecond Laser
Description: Fresh Corneal Lenticule Implantation using ReLex-Smile
Study: NCT02918318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal esketamine (28 mg)
Description: Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal esketamine (56 mg)
Description: Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal esketamine (84 mg)
Description: Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
Study: NCT03493945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1,200 mg IV once every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1,200 mg IV once every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1,200 mg IV once every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1,200 mg IV once every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1,200 mg IV once every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1,200 mg IV once every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1,200 mg IV once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: 8-15 mcg/kg subcutaneous every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: 8-15 mcg/kg subcutaneous every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: 8-15 mcg/kg subcutaneous every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: 8-15 mcg/kg subcutaneous every 2 weeks
Study: NCT02440919

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperoxygenation 20% FiO2
Description: Endotracheal suction associated with Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperinflation (PEEP- ZEEP) Basal FiO2
Description: Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and involved no hyperoxygenation, keeping the oxygen already offered to the patient.

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperinflation (PEEP- ZEEP) 20% FiO2
Description: Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and hyperoxygenation involved supplying 20% oxygen.
Study: NCT03493945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: 8-15 mcg/kg subcutaneous every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Brachyury
Description: MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Brachyury
Description: MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Brachyury
Description: MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Brachyury
Description: MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Brachyury
Description: MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Brachyury
Description: MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPV-Brachyury
Description: FPV-Brachyury will be given 2 weeks after second dose of MVA-BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPV-Brachyury
Description: FPV-Brachyury will be given 2 weeks after second dose of MVA-BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPV-Brachyury
Description: FPV-Brachyury will be given 2 weeks after second dose of MVA-BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPV-Brachyury
Description: FPV-Brachyury will be given 2 weeks after second dose of MVA-BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.
Study: NCT00780572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADE alert assistant
Description: A note in CPRS alerting providers that patients are at risk for an adverse event based on prescription and lab value histories.
Study: NCT02749903

Intervention type: DRUG
Group type: OTHER
Intervention: enzalutamide
Description: oral
Study: NCT02181231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: venlafaxine XR
Description: slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine XR
Description: slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: randomized to either buprenorphine or placebo, dose range from 0.2 mg/ qd to 2mg/ qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will remain on venlafaxine XR and be randomized to receive either placebo or buprenorphine for 8 weeks. at the end of the 8 weeks those who did not receive buprenorphine will be offered the opportunity to try it.
Study: NCT03372408

Intervention type: OTHER
Intervention: Chart review
Description: Retrospective chart review of program participation and socio-demographic \& psychosocial characteristics